Abstract
Simultaneous detection of multiple disease biomarkers in unprocessed whole blood is considered the gold standard for accurate clinical diagnosis. Here, we report the development of a 4-plex electrochemical (EC) immunosensor with on-chip negative control capable of detecting a range of biomarkers in small volumes (15 µL) of complex biological fluids, including serum, plasma, and whole blood. A framework for fabricating and optimizing multiplexed sandwich immunoassays is presented that is enabled by use of EC sensor chips coated with an ultra-selective, antifouling, nanocomposite coating. Cyclic voltammetry evaluation of sensor performance was carried out by monitoring the local precipitation of an electroactive product generated by horseradish peroxidase linked to a secondary antibody. EC immunosensors demonstrated high sensitivity and specificity without background signal with a limit of detection in single-digit pg/mL in multiple complex biological fluids. These multiplexed immunosensors enabled simultaneous detect of four different biomarkers in plasma and whole blood with excellent sensitivity and selectivity. This rapid and cost-effective biosensor platform can be further adapted for use with different high affinity probes for any biomarker, and thereby create for a new class of highly sensitive and specific multiplexed diagnostics.
Competing Interest Statement
This technology has been licensed to Antisoma Therapeutics Inc. for infectious disease and cancer diagnostics and to StataDX Inc. for neurological and kidney disease diagnostics; P.J. and D.E.I. hold equity in StataDx and D.E.I. is a board member; S.S.T., N.D., P.J., and D.E.I are also listed as inventors on patents describing this technology. RA is listed as inventor on a patent for the TB biomarkers (IL-6, IL-8, IL-18 and VEGF). The remaining authors declare no competing interests. We would like to acknowledge Linxens and Integrated Graphene for providing the electrodes for the study. This work was supported by the Wyss Institute for Biologically Inspired Engineering at Harvard University. MR was supported from Internal funding from bioengineering at UTD.
Funding Statement
We would like to acknowledge Linxens and Integrated Graphene for providing the electrodes for the study. This work was supported by the Wyss Institute for Biologically Inspired Engineering at Harvard University. MR was supported from Internal funding from bioengineering at UTD.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board for Harvard Human Research Protection Program (IRB21-0024)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors